Trump order would allow more VA research on medical marijuana

President Trump signed an executive order directing the DOJ to accelerate rescheduling marijuana from Schedule I to Schedule III to facilitate medical and CBD research; HHS, NIDA and the FDA have concurred that some medical uses exist. The order does not change federal law barring VA physicians from prescribing or covering cannabis, though the VA reports six ongoing studies (and 10 completed since 2010) on veteran-focused outcomes such as PTSD and chronic pain; prior congressional provisions to allow VA recommendations were removed from recent legislation. The move lowers federal research barriers and could incrementally benefit cannabis research funding and related companies over time, but it is not an immediate regulatory change to prescribing or VA benefits policy.

Analysis

Market structure: Rescheduling from Schedule I toward Schedule III materially favors US-facing multi-state operators (MSOs), ancillary services (CROs, testing labs), and banking/payment providers by lowering legal risk for research, insurance and capital flow. Expect a 6–36 month bifurcation where US MSOs capture share from illicit/fragmented markets and some Canadian LPs face margin pressure as pricing normalizes; near-term headline-driven equity volatility will be large (±20–40% swings in small-caps). Cross-asset: credit spreads for cannabis issuers should compress if regulatory clarity persists (5–10% tighter for best-in-class MSOs), while small-cap equity implied volatility will stay elevated, FX/commodities negligible.

Risk assessment: Tail risks include a reversal with a new administration or Congressional action that blocks rescheduling (low probability but >15% ahead of 2026 elections) and litigation delaying DOJ/HHS rule-making for 6–24 months. Immediate (days) sees headline pops; short-term (weeks–months) is funding and trial announcements; long-term (12–36 months) is clinical outcomes and insurance reimbursement. Hidden dependency: research acceptance by HHS/FDA does not equal prescribing rights or VA coverage — statutory fixes required, so commercial revenue impact likely delayed.

Trade implications: Direct tactical plays are liquid ETFs and select MSOs: express a 2–3% portfolio long via MSOS (US focus) and 1–2% concentrated longs in established MSOs (e.g., CURaleaf, Trulieve) with 12–24 month horizons. Use pair trade long MSOS / short MJ (global cannabis ETF) to capture domestic outperformance; implement 90-day call spreads on MSOS ahead of DOJ final rule (buy 10% OTM, sell 20% OTM) to limit capital at risk. Reduce leveraged exposure to small-cap Canadian LPs by ~30% and reallocate to CROs/testing labs if regulatory milestones hit.

Contrarian angles: The market may be overpricing immediate commercial upside—research access is necessary but insufficient for prescribing and insurance reimbursement; expect 20–50% mean reversion in small-cap names that rallied on the announcement. Historical parallel: post-Prohibition consolidation took 3–5 years; expect consolidation and margin compression before profitable scale. Unintended consequence: accelerated clinical trials could reveal adverse results that dent demand; position sizing and stop-loss discipline must anticipate binary regulatory/data shocks.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in MSOS (AdvisorShares Pure US Cannabis ETF) within 2 weeks to capture US-focused regulatory upside; set a profit target of +30% and a stop-loss at -15% over a 12-month horizon.
• Initiate 1–2% positions (each) in liquid MSOs with national footprints (e.g., CURLF/OTC Curaleaf, TCNNF/OTC Trulieve) with a 12–24 month hold; trim 50% on any single-name move >+50% and cut losses at -25%.
• Implement a 90-day call spread on MSOS prior to anticipated DOJ/HHS milestones: buy the 10% OTM call and sell the 20% OTM call (size to limit max loss to 0.5% of portfolio); if final rule published, roll/add to LEAPS within 30 days.
• Construct a pair trade: long MSOS (2%) / short MJ (1.5%) to express expected US outperformance vs global/canadian exposure; rebalance after any DOJ final rule or HHS statement within 30–90 days.
• Reduce leveraged or concentrated positions in small-cap Canadian LPs (CGC, TLRY, CRON exposure) by ~30% within 7 days and redeploy proceeds to CRO/testing lab names or cash until regulatory/clinical visibility improves (monitor DOJ Federal Register and HHS/FDA notices within next 30–90 days).